Diroximel fumarate

N/A

Report date: 2026/04/24 20:01:59
NME

Base Information

Drug NameDiroximel fumarate
Drug Alias Name富马酸地洛西美diroximeli fumarasfumarate de diroximelfumarato de diroximelVumerity +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor erythroid 2-related factor 2 stimulants
TargetsNuclear factor erythroid 2-related factor 2
Therapy Area/IndicationsPeripheral Vascular DiseasesPeripheral Arterial DiseaseArterial Occlusive Diseases +[6] 
Global Approved IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/10/29
Country/TerritoryBelgiumBulgariaCanada +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAlkermes Plc
China Registration ClassN/A

Develop Information

Active CompaniesBiogen Netherlands BvBiogen IncAlkermes Pharma Ireland Ltd +[7] 
Inactive CompaniesBanner Life Sciences Llc
Active IndicationsPeripheral Vascular DiseasesPeripheral Arterial DiseaseArterial Occlusive Diseases +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeL03
Related LinksDrugBankKEGG